Search Results
Dec 22, 2025, 08:01 ET TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit
More news about: TransCode Therapeutics, Inc.
Dec 19, 2025, 08:43 ET Mercury Bio and Meta-Flux Announce Strategic Collaboration to Advance Large-Molecule Therapeutics for Parkinson's and Alzheimer's Diseases
yeast extracellular vesicle (yEV™) technology - designed to deliver therapeutic proteins, RNA, and other large-molecule biologics into neurons, release them into the cytoplasm, and avoid endosomal degradation, including across the blood–brain
More news about: Mercury Bio Inc. & Meta-Flux
Dec 18, 2025, 09:00 ET Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Dec 17, 2025, 17:31 ET Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Novel Therapy Adoption Landscape | DelveInsight
and Phase IIb induction trials for ulcerative colitis. Its mechanism of action is distinct because it markedly increases miR-124 production, a unique RNA-splicing product with anti-inflammatory properties. Clinical evidence indicates that ABX464 may help patients achieve remission and promote healing of
More news about: DelveInsight Business Research, LLP
Dec 17, 2025, 16:01 ET Insmed Provides Clinical and Business Update
early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States,
More news about: Insmed Incorporated
Dec 17, 2025, 14:15 ET O segredo da musa! Sabrina Sato revela a sua rotina de cuidados com a pele para a temporada de verão e Carnaval
de aplicação F. Estudo de percepção realizado com 43 participantes.1. Waibel J, et al. Comparative Bulk RNA-Seq Analysis of Poly-l-Lactic Acid Versus Calcium Hydroxylapatite Reveals a Novel, Adipocyte-Mediated Regenerative Mechanism of Action Unique to PLLA.
More news about: Galderma
Dec 17, 2025, 09:00 ET Co-Diagnostics Performs Analysis of Influenza Co-Primers® to Confirm Reactivity Against Flu A H3N2 Mutation
diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Dec 17, 2025, 08:30 ET Xtalks Releases 2025 Webinar Year-in-Review Showcasing Key Life Science Trends
deploying AI in life sciences.Cell, Gene and RNA Therapies Continue to ScaleAdvanced therapeutic modalities remained a major focus in 2025, with webinars examining cell and gene therapy clinical development and safety, as well as RNA therapeutics, including mRNA characterization, quality
More news about: Xtalks
Dec 17, 2025, 08:00 ET Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for Cardiovascular Risk Reduction
Therapeutics is a world-leading RNAi therapeutics company dedicated to addressing cardiometabolic, obesity and degenerative diseases with next generation RNA technology platform. Since its inception in 2021, the Company has progressed four programs into the clinic leveraging its proprietary platform in delivery,
More news about: Rona Therapeutics
Dec 17, 2025, 08:00 ET Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for Cardiovascular Risk Reduction
Therapeutics is a world-leading RNAi therapeutics company dedicated to addressing cardiometabolic, obesity and degenerative diseases with next generation RNA technology platform. Since its inception in 2021, the Company has progressed four programs into the clinic leveraging its proprietary platform in delivery,
More news about: Rona Therapeutics
Dec 17, 2025, 07:00 ET Bioptimus Unveils M-Optimus, a World Model for Biology
complexity.This first version of M-Optimus integrates several biological modalities, including hematoxylin and eosin (H&E) stained histology images, bulk RNA sequencing, spatial transcriptomics, and clinical data, into a unified model. This is the first AI model in the world to combine multiple biological
More news about: Bioptimus
Dec 17, 2025, 07:00 ET Bioptimus Unveils M-Optimus, a World Model for Biology
complexity.This first version of M-Optimus integrates several biological modalities, including hematoxylin and eosin (H&E) stained histology images, bulk RNA sequencing, spatial transcriptomics, and clinical data, into a unified model. This is the first AI model in the world to combine multiple biological
More news about: Bioptimus
Dec 17, 2025, 06:50 ET Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
market and commercialize therapeutic programs."This collaboration represents our first expansion into the rare kidney disease space leveraging RNA technologies, demonstrating the implementation of our previously updated research strategy," said Dror Bashan, Protalix's President and Chief Executive
More news about: Protalix BioTherapeutics, Inc.; Secarna Pharmaceuticals
Dec 17, 2025, 05:30 ET Norgine potenzia il portafoglio di prodotti epatologici e speciali attraverso un accordo di licenza esclusivo concluso con Vir Biotechnology
vari meccanismi. Tobevibart è un anticorpo monoclonale neutralizzante sperimentale progettato per l'interazione immunitaria. Elebsiran è un piccolo RNA interferente (siRNA) sperimentale progettato per consentire la distribuzione mirata al fegato e per ridurre l'antigene di superficie dell'epatite B,
More news about: Norgine Pharmaceuticals Limited
Dec 17, 2025, 05:23 ET Norgine erweitert sein Hepatologie- und Spezialitätenportfolio durch exklusive Einlizenzierungsvereinbarung mit Vir Biotechnology
monoklonaler Antikörper, der für den Einsatz im Immunsystem entwickelt wurde. Elebsiran ist eine in der Erprobung befindliche kleine interferierende RNA (siRNA), die eine gezielte Abgabe an die Leber ermöglichen und das Hepatitis-B-Oberflächenantigen reduzieren soll, ein Protein, das für den Lebenszyklus
More news about: Norgine Pharmaceuticals Limited
Dec 17, 2025, 03:01 ET Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology
an investigational neutralising monoclonal antibody that has been engineered for immune engagement. Elebsiran is an investigational small interfering RNA (siRNA) that is designed to enable targeted delivery to the liver and to reduce hepatitis B surface antigen, a protein which is required for the hepatitis
More news about: Norgine Pharmaceuticals Limited
Dec 17, 2025, 03:01 ET Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology
an investigational neutralising monoclonal antibody that has been engineered for immune engagement. Elebsiran is an investigational small interfering RNA (siRNA) that is designed to enable targeted delivery to the liver and to reduce hepatitis B surface antigen, a protein which is required for the hepatitis
More news about: Norgine Pharmaceuticals Limited
Dec 16, 2025, 17:05 ET The Next Chapter in Obesity Therapeutics: Vial's INHBE siRNA Draws KOL Praise as a Next-Generation Obesity Therapy
including General Catalyst, Buckley Ventures, and Byers Capital. Vial is focused on advancing a pipeline of potentially best-in-class biologics and RNA therapeutics across areas of unmet medical need. Founded in 2020, Vial is a multidisciplinary team across R&D, Clinical Development, Clinical Operations,
More news about: Vial
Dec 16, 2025, 10:00 ET Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors
the seamless removal, repair, or insertion of both small and large DNA sequences, offering broad therapeutic potential, coupled with single AAV or all-RNA delivery. Dualase® achieves best-in-class accurate editing efficiency with undetectable off-target effects as demonstrated in preclinical cell and animal
More news about: Specific Biologics Inc.
Dec 16, 2025, 10:00 ET Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors
the seamless removal, repair, or insertion of both small and large DNA sequences, offering broad therapeutic potential, coupled with single AAV or all-RNA delivery. Dualase® achieves best-in-class accurate editing efficiency with undetectable off-target effects as demonstrated in preclinical cell and animal
More news about: Specific Biologics Inc.
Dec 16, 2025, 07:00 ET RNAConnect Launches the UltraMarathonRT® Direct RNA‑Seq Kit to Advance Nanopore-based Native RNA Sequencing
generation tools to the RNA community, today announced the commercial availability of the UltraMarathonRT® Direct RNA‑Seq (uMRT DRS) Kit, a native‑RNA library preparation solution for Oxford Nanopore Technologies® direct RNA sequencing (SQK-RNA004). The kit enables the
More news about: RNAConnect
Dec 16, 2025, 07:00 ET Replicate Bioscience Appoints Kathy Fernando, Ph.D., as Chief Business Officer
Weissman.About Replicate BioscienceReplicate Bioscience is a clinical-stage company amplifying the power of RNA therapeutics by pioneering its novel self-replicating RNA (srRNA) technology to overcome the shortcomings of existing mRNA approaches, with potential improvements in bioactivity,
More news about: Replicate Bioscience
Dec 15, 2025, 20:34 ET Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
Therapeutics is a world-leading RNAi therapeutics company dedicated to addressing cardiometabolic, obesity and degenerative diseases with next generation RNA technology platform. Since its inception in 2021, the Company has progressed four programs into the clinic leveraging its proprietary platform in delivery,
More news about: Rona Therapeutics
Dec 15, 2025, 11:01 ET UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE NAMES DISTINGUISHED SCIENTIST AND ACADEMIC LEADER GERALD M. WILSON, PHD, AS CHAIR OF THE DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY
15, 2025. Dr. Wilson, a distinguished scientist and educator, brings more than two decades of leadership and internationally recognized research in RNA biochemistry and cancer mechanisms to this role. As part of the appointment, he will be endowed as the John F.B. Weaver Professor in Biochemistry and
More news about: University of Maryland Medical Center
Dec 15, 2025, 09:05 ET Pivot Bio Announces Additions to Senior Management
fruit yield. Liberatore completed her Bachelor of Science degree in biology at the University of New Mexico, where she studied DNA damage response and RNA splicing. She also conducted field research at the Lizard Island Research Station in the Great Barrier Reef through the UNM honors and NIH Post-baccalaureate
More news about: Pivot Bio, Inc